Joseph P. Herbert, MD
Dr. Herbert is a 2nd year Neurological Surgery Resident at the University of Missouri, Columbia.
He earned his Medical Degree at the University of Texas Medical School, in Houston Texas.
He also earned a BS in Cell and Molecular Biology, Magna Cum Laude with Honors, at Texas Tech University, Lubbock, Texas.
Dr. Herbert has many honors/awards, which include: Earl Camp Award for most outstanding graduating senior of the Department of Biological Sciences; Presidential Endowed Scholarship; Pre-Medical Scholarship; Goodin Cell and Molecular Biology Scholarship; Honors College Study Abroad Scholarship all from Texas Tech University.
Dr. Herbert has many accomplishments, publications, posters, presentations, and Research a partial list which include: Publication: The Relationship of cortical folding/brain arteriovenous malformations; Neurovasc Imaging, 2016. Publication: Simultaneous Repair of Right-Sided Coarctation and Vascular Ring; Ann Thorac Surg, 2015. Presentations/Posters: “Pediatric Blunt Cerebrovascular Injury: the McGovern Experience.” The pterional approach to the pituitary: historical perspectives and a case report. The transnasal approach to the pituitary: history and technique. Research Experience: Currently generating database of coagulation studies on admission in traumatic brain injury patients, specifically their admission platelet function and their response clinically to platelet transfusion. Involved in preparing a proposal for an inaugural $100,000 seed grant through the University of Texas Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. Reported the UT institutional experience using Gamma Knife radiosurgery with and without anti-VEGF chemotherapy as salvage therapy for recurrent glioblastoma multiforme. Assisted to investigate the relationship of developmental cortical folding and arteriovenous malformation (AVM) pathogenesis using advanced MRI techniques. Conducted an extensive retrospective study on incidence of blunt cerebrovascular injury (BCVI) in the pediatric population.
Researched pediatric cancers; Specifically, worked to develop novel therapeutic strategies for a variety of cancers, especially neuroblastoma and leukemia. In charge of three main projects including 1) Worked to determine mitochondrial morphological changes in response to treatment with the Vitamin-A derivative, fenretinide.
2) Completed the in vitro testing of a novel therapeutic combination, fenretinide and the ALK inhibitor crizotinib, in neuroblastoma. 3) worked to develop a novel technique to enable physicians to enrich circulating tumor cells for genomic analysis in order to elucidate targetable genetic mutations.